Guru Sonpavde, MD, on phase 3 AMBASSADOR trial data in urothelial carcinoma
The AMBASSADOR trial, presented at ESMO 2024, evaluated adjuvant pembrolizumab in high-risk muscle-invasive urothelial carcinoma, showing maintained DFS improvement with a hazard ratio of 0.7. The trial supports pembrolizumab's potential role in adjuvant therapy, though survival data is not yet conclusive. No trend for improved outcomes in PD-L1 high population was observed, but a trend favoring bladder primary over upper tract was noted.
Reference News
The AMBASSADOR trial, presented at ESMO 2024, evaluated adjuvant pembrolizumab in high-risk muscle-invasive urothelial carcinoma, showing maintained DFS improvement with a hazard ratio of 0.7. The trial supports pembrolizumab's potential role in adjuvant therapy, though survival data is not yet conclusive. No trend for improved outcomes in PD-L1 high population was observed, but a trend favoring bladder primary over upper tract was noted.